Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Cardiff Oncology, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 73 | 90 | +17 |
| Shares | 24.1M | 26.5M | +2.45M (+10.2%) |
| Value | $223.0M | $176.4M | −$46.6M (−20.9%) |
New holders (32)
Institutions that held Cardiff Oncology, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (15)
Institutions that held Cardiff Oncology, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Pictet Asset Management Ltd | 581,907 | $5.39M |
| Millennium Management LLC | 322,962 | $2.99M |
| Frazier Management LLC | 293,500 | $2.72M |
| HRT Financial LP | 283,885 | $2.63M |
| FMR LLC | 149,780 | $1.39M |
| Soleus Capital Management, L.P. | 42,684 | $395.0K |
| Migdal Insurance & Financial Holdings Ltd. | 33,064 | $306.0K |
| Jane Street Group, LLC | 27,057 | $251.0K |
| Prospera Financial Services Inc | 26,650 | $247.0K |
| LMR Partners LLP | 23,332 | $216.0K |
| Ensign Peak Advisors, Inc | 22,123 | $205.0K |
| Blueshift Asset Management, LLC | 14,487 | $134.0K |
| Maven Securities LTD | 5,484 | $51.0K |
| Valeo Financial Advisors, LLC | 2,250 | $21.0K |
| Bank of Montreal | 310 | $3.00K |